Alteplase: Stability and bioactivity after dilution in normal saline solution

Journal of Vascular and Interventional Radiology

Volumn 14, Issue 1, 2003, Pages 99-102

  Semba, Charles P ^a   Weck, Suzanne ^a   Patapoff, Thomas ^a  

^a NONE

Author keywords

Thrombolysis; Tissue type plasminogen activator

Indexed keywords

ALTEPLASE; CATHFLO ACTIVASE; SODIUM CHLORIDE;

ARTICLE; BLOOD CLOT LYSIS; DILUTION; DRUG ACTIVITY; DRUG STABILITY; DRUG STORAGE; ENVIRONMENTAL TEMPERATURE; PH; PRIORITY JOURNAL; PROTEIN CONTENT;

EID: 0037252809     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000052297.26939.05     Document Type: Article

References (15)

1. Cathflo Activase: full prescribing information. In: Physicians Desk Reference. Montvale, NJ: Thomas Medical Economics, 2002.
2. Activase: full prescribing information. In: Physicians Desk Reference. Montvale, NJ: Thomas Medical Economics, 2002.
3. Valji K. Evolving strategies for thrombolytic therapy of vascular occlusion. J Vasc Interv Radiol 2000; 11:411-420.
4. Semba CP, Sugimoto K, Razavi MK. Alteplase and tenecteplase: applications in the peripheral circulation. Tech Vasc Intervent Radiol 2001; 4:99-106.
5. Semba CP, Bakal CW, Calis KA, et al. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy. J Vasc Interv Radiol 2000; 11:279-287.
6. Bookstein JJ, Bookstein FL. Augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude. J Vasc Interv Radiol 2000; 11:299-303.
7. Bookstein JJ, Bookstein FL. Plasminogen-enriched pulse-spray thrombolysis with t-PA: further developments. J Vasc Interv Radiol 2000; 11:1353-1362.
8. United States Pharmaceopeia. Available at www.usp.org. Accessed August 2002.
9. Jones AJ, Meunier AM. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis. Thromb Haemost 1990; 30:455-463.
10. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985; 54:684-687.
11. Dotter CT, Rosch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974; 111:31-37.
12. Food and Drug Administration. FDA Letter. Important Drug Warning: safety information regarding the use of Abbokinase (urokinase), January 1999. Available at: www: fda.gov/cber/ltr/abb012599.htm. Accessed August 2002.
13. Ouriel K, Gray B, Clair DG, Olin J. Complications associated with use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol 2000; 11:295-298.
14. McNamara TO, Chen JL, Temmins CJ, Quinn B. Bleeding associated with intrathrombus infusions of t-PA for peripheral arterial and venous occlusions (abstract). Am J Cardiol 1999; 84(6A):37P.
15. Cornelius RM, Archambault JG, Berry L, Chan AK, Brash JL. Adsorption of protein from infant and adult plasma to biomaterial surfaces. J Biomed Mater Res 2000; 15:622-632.